A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.

Klaus F Rabe,Fernando J Martinez,Gary T Ferguson,Chen Wang,Dave Singh,Jadwiga A Wedzicha,Roopa Trivedi,Earl St Rose,Shaila Ballal,Julie McLaren,Patrick Darken,Colin Reisner,Paul Dorinsky

Respiratory Medicine（2019）

引用 33|浏览24

暂无评分

摘要

•Budesonide/glycopyrrolate/formoterol metered dose inhaler is a triple therapy for COPD.•ETHOS will investigate exacerbations, patient-related outcomes, safety & mortality.•> 8500 patients with moderate-to-very severe COPD.•Triple therapy with 2 different ICS doses will be compared to ICS/LABA and LAMA/LABA.•Findings are expected to help refine current treatment recommendations.

查看译文

关键词

BGF MDI,Chronic obstructive pulmonary disease,Exacerbations,Inhaled corticosteroid,Study protocol,Triple therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.